Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TPXRP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
sofetabart mipitecan
|
|||||
| Synonyms |
sofetabart mipitecan; MBK-103; LY4170156
Click to Show/Hide
|
|||||
| Organization |
Mablink Bioscience (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 3
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Sofetabart
|
Antibody Info | ||||
| Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mal-Polysarcosine10-Val-Ala-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
mipitecan
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
||||||||||
| Cervical cancer |
1 Trials
|
||||||||||
| Colorectal cancer |
1 Trials
|
||||||||||
| Endometrial cancer |
1 Trials
|
||||||||||
| Fallopian tube cancer |
1 Trials
|
||||||||||
| Lung cancer |
1 Trials
|
||||||||||
| Ovarian cancer |
1 Trials
|
1 Trials
|
|||||||||
| Pancreatic cancer |
1 Trials
|
||||||||||
| Peritoneal cancer |
1 Trials
|